Elizabeth Froman
General Practice · Springdale, ARNPI 1821031295
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $168,850 of the $169,683 with a category attached, or 99.5%. 22 manufacturers reported payments, led by CSL Plasma Inc. at 54.5% of the total. 2025 is the largest year on record at $31,475, more than ten times the $69 reported in 2019. Among general practice clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $902.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$92K
- CSL Behring$76K
- Ironshore Pharmaceuticals Inc.$189
- Corium, LLC$116
- Collegium Pharmaceutical, Inc.$77
- Otsuka America Pharmaceutical, Inc.$64
- plus $387 from 16 others
What the payments were for
- Consulting fees$168,850100%
- Food & beverage$8330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 71 | $92,400 |
| CSL Behring | 66 | $76,450 |
| Ironshore Pharmaceuticals Inc. | 10 | $189 |
| Corium, LLC | 11 | $116 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Sanofi Pasteur Inc. | 3 | $47 |
| Eisai Inc. | 3 | $44 |
| AstraZeneca | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| The Binding Site Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Biogen | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Biocompatibles, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$169,683 in reported general payments places this provider in the 95th percentile of 720 general practice providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 22 | $30,326 |
| Fluvoxamine Maleate | 12 | $341 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $281 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $14 | $30,32622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 720 general practice providers in Arkansas.
Other general practice in Springdale
- David FurrSpringdale$9K
- Dwight DuckworthSpringdale$4K
- Eric WoodSpringdale$3K
- Johnny AdkinsFayetteville$172K
- Samuel StrongLittle Rock$27K
- Daniel RyderRussellville$18K
- Nicholas CulpepperRogers$16K
- Thomas JeffersonLittle Rock$13K
- Joe BufordNorth Little Rock$9K
- Tina NicholsLittle Rock$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.